BiotechTube
Tenaya Therapeutics

Tenaya Therapeutics

TNYA
South San Francisco, United States
tenayatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

TNYA · Stock Price

USD 0.85+0.43 (+104.83%)
Market Cap: $184.8M

Historical price data

Overview

Tenaya Therapeutics is a clinical-stage biotech dedicated to discovering and delivering curative therapies for the underlying genetic drivers of heart disease. The company has reported promising early clinical data for its two lead gene therapy programs, TN-201 for MYBPC3-associated HCM and TN-401 for PKP2-associated ARVC, and is advancing a preclinical small molecule, TN-301, for Duchenne muscular dystrophy. Its strategy leverages a precision medicine approach, validated genetic targets, and a multi-modal platform to address significant unmet needs in cardiovascular and neuromuscular diseases.

CardiovascularNeuromuscular

Technology Platform

Multi-modal platform integrating AAV-based cardiac gene therapy for precise genetic replacement and a small molecule HDAC6 inhibitor platform targeting pathways of muscle decline and fibrosis.

Funding History

4
Total raised:$368M
IPO$120M
Series C$106M
Series B$92M
Series A$50M

Opportunities

Tenaya has first-mover potential in developing curative gene therapies for two serious inherited cardiomyopathies (MYBPC3-HCM and PKP2-ARVC) with no disease-modifying treatments.
Its multi-modal approach, including a differentiated HDAC6 inhibitor for DMD, diversifies its pipeline across cardiovascular and neuromuscular high-need markets.

Risk Factors

The company faces significant clinical, regulatory, and manufacturing risks inherent to AAV gene therapy development.
As a pre-revenue company with a low market cap, it is highly vulnerable to clinical setbacks and faces substantial dilution risk if additional capital is required.

Competitive Landscape

Tenaya is a clinical leader in gene therapy for specific inherited cardiomyopathies with few direct competitors. In DMD, TN-301 must differentiate itself from approved therapies and other HDAC inhibitors based on its selective mechanism and potential cardiac benefits.

More companies in United States →